Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Successful Treatment With Minocycline and Saiko-Keishi-to for Covid-19-Associated CNS Lesion

Version 1 : Received: 3 November 2022 / Approved: 8 November 2022 / Online: 8 November 2022 (10:28:06 CET)

How to cite: Ohe, M.; Haruki, S.; Yamamoto, J.; Seki, M.; Furuya, K. Successful Treatment With Minocycline and Saiko-Keishi-to for Covid-19-Associated CNS Lesion. Preprints 2022, 2022110153. https://doi.org/10.20944/preprints202211.0153.v1 Ohe, M.; Haruki, S.; Yamamoto, J.; Seki, M.; Furuya, K. Successful Treatment With Minocycline and Saiko-Keishi-to for Covid-19-Associated CNS Lesion. Preprints 2022, 2022110153. https://doi.org/10.20944/preprints202211.0153.v1

Abstract

Neuropsychiatric manifestations of COVID-19 include delirium, general malaise, headache, and psychiatric symptoms. These manifestations are related to the neuroinflammatory response to viral antigens and proinflammatory mediators/immune cells. Tetracyclines, such as minocycline, have antibacterial and anti-inflammatory properties. Saiko-keishi-to, a traditional Japanese Kampo medicine, also has anti-inflammatory properties. Given the anti-inflammatory properties of minocycline and Saiko-keishi-to, we describe two cases of COVID-19 with prolonged headaches and general malaise successfully treated with these medications.

Keywords

COVID-19; minocycline; saiko-keishi-to

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.